fbpx

YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Stronger Macro Data + Lower Rates Propel Markets Higher on Thursday – UNH , HL, KDNY Jump!

By John F. Heerdink, Jr.


QUOTE OF THE DAY – “It’s far better to buy a wonderful company at a fair price, than a fair company at a wonderful price.” — Warren Buffett 

Happy Thursday!

I hope that the markets treated you well again today. All indices moved higher as the S&P 500 closed at 4,179.42 (+1.11%), the Dow ended at 34,035.99 (+.9%), the Nasdaq closed at 14,038.76 (+1.31%), while the smalls on the Russell 2000 ended at 2,257.07 (+.42%).  9 of 11 sectors ended in the green with the real estate sector up 2%, the information technology sector up 1.8%, & the health care sector up 1.7% leading the way. 

Overall the markets seemed to gain momentum on the backs of multiple macroeconomic reports that continued to exhibit increasing strength. The March retail sales report confirmed and impressive 9.8% jump month/month that was surely bolstered by the stimulus measures that put free money in the hands of many Americans. The bar & restaurant industry saw an out weighted gain of 13.4% as more people got out and had money to burn.  The Initial jobless claims report for the week ending April 10 confirmed a drop by 193k to 576k while continuing claims for the week ending April 3 showed a rise of 4k to 3.731M. The total industrial production report confirmed a rise by 1.4% month/month in March while the capacity utilization rate moved higher to 74.4%. The Philadelphia Fed Index report showed a rise to 50.2 in April. The Empire State Manufacturing Survey rose to 26.3 in April. The NAHB Housing Market Index moved up to 83 in April. Business inventories rose .5% month/month in February.

Two majors banks beat Wall Street earnings estimates including Bank of America (BAC, $38.74, -2.86% & Citigroup (C, $72.54, -.51%), however with long term interest rates pulling back & flattening again today theses stocks did not fair well. well. The 10-yr yield fell 11 basis points to end at 1.53% and the 2-yr yield fell 1 basis point to end at 0.14%. The U.S. Dollar Index also fell .1% to end at 91.62. The financials sector closed lower by .1.

Dow 30 component and healthcare giant UnitedHealth (UNH) closed at $390.01, +3.8% post today’s earnings beat that they married with a move to raise FY21 EPS guidance.

Oil prices continues higher moving up .4% to close at $63.44/bbl.

The FAANG stocks regained form today and higher as follows: Apple (AAPL) shares closed at $134.50, +1.87% & Amazon (AMZN) closed at $3,379.09, +1.38% as Jeff Bezos delivered his victory lap and last letter to shareholders telling us all how well he did to help us make money over the years and get us the stuff that we want quickly at the touch of a button. Alphabet (GOOG) closed at $2,296.66, +1.85%, Facebook (FB) also closed at $307.82, +1.65% & Netflix (NFLX) closed at $549.22/share, +1.7%. The MicroSectors FANG+ Index 3X Leveraged ETN (FNGU), which offers 3x leveraged exposure to an index of “FANG” companies, and other companies that exhibit similar characteristics, closed at $35.94, +4.72%.

EV giant and Elon Musk led Tesla (TSLA) closed higher at $738.85, +.9%.  

The iShares Nasdaq Biotechnology ETF (IBB) closed higher for the 3rd consecutive day closing at 153.19, +1.22%, while the NYSE ARCA Biotech Index (^BTK) closed at 5,551.67, +1.22%. Today, Chinook Therapeutics’ (KDNY, $15.24, +10.43%) CEO Eric Dobmeier  & CBO Tom Frohlich delivered their presentation titled “Revolutionizing The Treatment of Kidney Disease” followed by a Q&A session at the Tribe Public Network. You can view the video of the event here.  Chinook is focused on severe chronic kidney diseases with well-defined clinical pathways. Their lead clinical program, atrasentan, is an endothelin receptor antagonist that was in-licensed from AbbVie in 2019. The phase 3 ALIGN trial of atrasentan is currently enrolling patients with IgA nephropathy and the phase 2 AFFINITY trial of atrasentan is currently enrolling patients with proteinuric glomerular diseases. BION-1301, an investigational anti-APRIL monoclonal antibody, is being evaluated in a phase 1b trial for IgA nephropathy. They are also advancing CHK-336 for the treatment of primary hyperoxaluria towards a planned IND submission in late 2021/early 2022. In addition, they are conducting research programs in other rare, severe chronic kidney diseases. They seek to build our pipeline by leveraging insights in single cell RNA sequencing of patient kidney samples, human-derived organoids and new translational models in order to discover and develop therapeutics with mechanisms of action targeted against key kidney disease pathways.

The iShares Silver Trust ETF (SLV) closed at $24.03, +1.87% & the SPDR Gold Shares (GLD) closed at $165.35, +1.62%. Silver prices closed at $25.88/oz, +.43. Gold prices closed at 1,766, +$28. Hecla Mining (HL) closed at $6.52, +6.19%.

Crypto’s Ethereum flew up to eclipse $2,500 today.

Morgan Stanley (NS), The PNC Financial Services Group (PNC), Ally Financial (ALLY) & State Street Corp. (STT) report earnings tomorrow. 

We will also receive the Housing Starts and Building Permits report for March & the preliminary University of Michigan Index of Consumer Sentiment report for April.

VP WATCHLIST HIGHLIGHTS


You can review our complete VP Watchlist that we believe deserve consideration for short term and long term portfolio adds that include Apple, Tesla, & seven other names. The pages will enable you to stay informed and learn more about these companies daily.

Please review few of the updates on a few of the VP Watchlist companies below: 


  • Natural-Killer cell (NKcell) focused biopharmaceutical firm Fate Therapeutics (FATE) closed at $84.40/share, -.39%.

    • On March 25, FATE announced that Daniel D. Shoemaker, Ph.D., Chief Scientific Officer, has advised the Company that he is retiring as of June 30, 2021 after more than 12 years with the Company. Dr. Shoemaker has been with Fate Therapeutics since February 2009, having served as the Company’s Chief Scientific Officer since May 2015. Bob Valamehr, Ph.D., Chief Research and Development Officer of Fate Therapeutics and scientific leader of its iPSC Product Platform since January 2010, will continue to lead all research and development activities.
    • On Dec. 6, 2020, Fate presented a patient case study from the Company’s Phase 1 clinical trial of FT596, its universal, off-the-shelf, CD19-targeted chimeric antigen receptor (CAR) natural killer (NK) cell product candidate, at the 62nd Annual Society of Hematology Annual Meeting and Exposition and the street loved it. NK cells are the body’s first line of defense against viral infections and cancerous cells with an innate ability to rapidly seek and destroy transformed cells. NK cell therapy has the potential to 1) target multiple pathogenic antigens with measurably more efficient cytotoxicity, 2) be better controlled to reduce risk of cytokine storms and 3) be produced from a variety of sources without relying on patient-specific immune cells. Dr. Wayne Chu, Senior Vice President, Clinical Development of Fate Therapeutics stated, “The safety, pharmacokinetics and clinical activity observed following both the first and second single-dose treatment cycles of FT596 are compelling, especially when considering that the administered cell dose was significantly lower than the recommended cell dose of FDA-approved autologous CD19-targeted CAR T-cell therapies and that the heavily pre-treated patient was refractory to last prior therapy. We are excited the CAR component of FT596 has shown clinical activity at this low dose level, and we continue to enroll patients in dose escalation with FT596 as a monotherapy and in combination with rituximab.”


  • INVO Bioscience (NASDAQ: INVO) is a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world’s only in vivo Intravaginal Culture System. Shares INVO closed at $3.85/share, -1.28%.
    • On April 13,  I hosted INVO’s CEO Steve Shum at the Tribe Public CEO Presentation – Q&A Webinar Event where he delivered his presentation is titled “Democratizing Infertility – A Severely Underserved Global Market.” You may view the video of the event now at his link: https://youtu.be/w4yQIc7eO5k.
    • After the close March 30, INVO announced 2020 financial results and highlights.  Steve Shum, Chief Executive Officer of INVO Bioscience stated, “In the face of a difficult year for many industries, including the fertility business, I am extremely proud of the accomplishments of the entire INVO Bioscience team. During the year, we put in place a number of building blocks for the future, which are already beginning to pay dividends. Recently we announced our plan to open our first U.S.-based INVOcell clinic in partnership with some of the most highly accomplished INVOcell practitioners in the world. Our partners are not only extremely well-versed in the INVOcell technology, but also have a proven track record of successful implementation of the platform within an established clinical setting. A few months prior, we announced that we plan to open dedicated INVOcell clinics in Mexico with Dr. Francisco Arredondo and Dr. Ramiro Ramirez, who were also early adopters of the INVOcell solution and have established a successful track record of successful implementation of INVOcell in a clinical setting. We believe the combination of strong distribution partners such as Ferring in the U.S. and other locations around the world, coupled with dedicated INVOcell clinics partnerships which INVO Bioscience has an equity interest in, position the Company well for the future. Another key development during the year was the availability of additional positive real-world usage data highlighting the success of INVOcell, including a published peer-reviewed manuscript (report). We expect to see further data from this year’s SART information in the near future. In our opinion, this expanded retrospective, real world validated data is extremely valuable to our commercial efforts and builds confidence with practitioners. We believe that this expanding portfolio of usage data will play an important role in expanding and accelerating market adoption.”
    • On March 8, INVO announced that they has agreed to an amendment of their agreement with Ferring Pharmaceuticals that provides for an increase in the number of INVO company-owned US-based clinics initially allowable under the agreement and removes certain geographical restrictions. The amendment also adjusted the remaining annual 2020 minimum contractual product purchase requirement, whereby Ferring will place a $501,000 order, which will be recognized as revenue by INVO Bioscience in the first quarter of 2021. READ STORY.
    • On March 1, INVO announced the Company has received approval by COFEPRIS to import INVOcell into Mexico. In late 2020, INVO Bioscience established a joint venture focused on establishing fertility centers dedicated to offering INVOcell, with the initial center, called Positib Fertility, to be located in the city of Monterrey, Mexico. Steve Shum, CEO of INVO Bioscience, commented, “We are extremely pleased to have received approval by COFEPRIS to begin importing INVOcell into Mexico. This was a key step in the process to open our first joint venture owned clinic in the large and growing Mexico market for infertility services. Our internal team along with our JV partners have and continue to work aggressively and with a relentless focus to bring the INVOcell treatment option to the many patients in need of care within Mexico.”
    • On Jan. 27, INVO announced that it has advanced its commercialization efforts into the European fertility market by securing initial orders of INVOcell in Madrid and Barcelona, Spain. INVOcell will initially be available at three separate existing fertility clinics which have placed orders and commenced training. Please read the story here.
    • INVO’s Management Issued a letter to shareholders on Jan. 7 that spoke to their key developments and future initiatives that have positioned their product INVOcell® within the severely underserved fertility market. PLEASE read the story here.
    • Industry forecasts suggest that only 1% to 2% of the estimated 150 million infertile couples worldwide are currently being treated. INVO’s mission is to increase access to care and expand infertility treatment across the globe with a goal of improving patient affordability and industry capacity.
  •  


  • Shares of Chinook Therapeutics (KDNY), a clinical-stage biotechnology company developing precision medicines for kidney diseases, closed today at $15.24, +10.43%.
    • Today, April 15, Chinook announced six poster presentations at the ISN World Congress of Nephrology 2021 (WCN ’21). Eric Dobmeier, president and chief executive officer of Chinook stated, “The depth and breadth of our presence at this year’s WCN ’21 is a testament to Chinook’s role as a leading kidney disease company. Our data demonstrating BION-1301’s ability to significantly reduce Gd-IgA1 levels in healthy volunteers, as well as the favorable pharmacodynamics of subcutaneous administration of BION-1301, position the program well to move forward in demonstrating its disease-modifying potential for IgA nephropathy patients. In addition, our preclinical poster presentations on atrasentan provide broader insights into its anti-fibrotic and anti-inflammatory properties that are additive and complementary to its proteinuria-lowering mechanism of action.”
    • Today, April 15, Chinook’s CEO Eric Dobmeier  & CBO Tom Frohlich delivered a presentation titled “Revolutionizing The Treatment of Kidney Disease” followed by a Q&A session at the Tribe Public Network. You can view the video of the event here. 
    • On April 7, KDNY provided a business update and reported financial results for the full year ended December 31, 2020. Eric Dobmeier, President and chief executive officer of Chinook Therapeutics stated, “We are executing well on our goal of building Chinook into a leading kidney disease company. 2020 was a very busy and productive year, as we in-licensed atrasentan from AbbVie, closed a $115 million financing, brought BION-1301 into our pipeline through the merger with Aduro, unveiled CHK-336, our first internally-developed program, and bolstered our precision medicine discovery and research efforts. We are excited to have recently initiated our atrasentan phase 3 ALIGN and phase 2 AFFINITY trials and announced our collaboration with Evotec. We look forward to multiple data announcements from our BION-1301 program this year, as well as continuing to move CHK-336 towards the clinic. Our team has grown over 300 percent since the beginning of 2020, and we’re continuing to execute on our hiring plans to ensure we have strong resourcing in place to advance our pipeline. Our solid cash position, which we expect to fund our operations to the middle of 2023, enables us to achieve key milestones across our programs.”
    • On Monday, April 5th, KDNY announced a transaction with Van Herk Investments, a leading European life science investor, to create and fund a new company called Sairopa, with a pipeline focused on research and development of non-renal monoclonal antibodies generated through Aduro Biotech’s B-Select platform. Chinook will own approximately 40 percent of Sairopa after the first tranche of financing from Van Herk and have one seat on Sairopa’s Board of Directors.
    • On March 16, Chinook announced that the first patient with IgA nephropathy (IgAN) has been enrolled in the ALIGN Study, a pivotal phase 3 clinical trial evaluating the efficacy and safety of atrasentan, a potent and selective inhibitor of the endothelin A receptor. “The initiation of the phase 3 ALIGN Study is an important milestone for Chinook as we advance our pipeline of programs for rare, severe chronic kidney diseases,” said Alan Glicklich, M.D., chief medical officer of Chinook. “Atrasentan has been studied in over 5,300 diabetic kidney disease patients in the phase 2 RADAR and phase 3 SONAR studies, demonstrating rapid, sustained proteinuria reductions of approximately 30 to 35 percent as well as improved eGFR. Importantly, treatment with atrasentan also resulted in a reduction in clinical outcomes of development of end-stage kidney disease and doubling of serum creatinine. We look forward to exploring the proteinuria-lowering, anti-inflammatory and anti-fibrotic effects of atrasentan in patients with IgA nephropathy, a serious progressive disease for which there are no approved therapies.”

    • On March 1, Chinook and Evotec SE announced a strategic collaboration focused on the discovery and development of novel precision medicine therapies for patients with chronic kidney diseases. Based on Evotec’s proprietary comprehensive molecular datasets from thousands of patients across chronic kidney diseases of multiple underlying etiologies, Chinook and Evotec will jointly identify, characterize and validate novel mechanisms and discover precision medicines for PKD, lupus nephritis, IgA nephropathy and other primary glomerular diseases. The collaboration will also involve further characterization of pathways and patient stratification strategies for programs currently in Chinook’s clinical and preclinical pipeline. “We are excited to embark on this strategic collaboration with Evotec, the leading drug discovery alliance and development partner in nephrology,” said Andrew King, D.V.M., Ph.D., Head of Renal Discovery and Translational Medicine at Chinook. “Gaining access to the NURTuRE cohort study and other proprietary patient biobanks, along with Evotec’s multi-omics integration platform, will enable us to define the molecular drivers of kidney diseases, identify novel targets for drug development in selected patient sub-populations and continue to build the foundation for our precision medicine approach. With a focus on comprehensive molecular disease classification, combined with prospective clinical outcomes, Chinook has the opportunity to potentially deliver targeted therapies to the right patient populations.”
    • On Feb. 2nd, Chinook announced that the U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation for CHK-336, an investigational oral small molecule inhibitor of lactate dehydrogenase A (LDHA) for primary hyperoxaluria (PH). PH is a group (PH1, PH2 and PH3) of ultra-rare genetic diseases caused by enzyme mutations that result in excess oxalate production in the liver, and in its most severe forms, can lead to end-stage kidney disease at a young age. Inhibition of LDHA with CHK-336 allows for the potential to treat all forms of PH and other disorders arising from excess oxalate, while its liver-targeted tissue distribution profile enables maximal inhibition of liver oxalate production with minimal systemic exposure. Please read the story here.
  •  


  • Shares of Seattle-based Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, closed at $1.73, -6.99%.
    • On April 8, Atossa announced that an ovarian cancer patient has begun treatment with Atossa’s proprietary oral Endoxifen. The FDA previously issued a “Safe to Proceed” letter under their expanded access pathway, permitting the use of Atossa’s oral Endoxifen in this patient. The patient is being treated at the University of Washington Medical Center by Dr. Barbara Goff, Surgeon-in-Chief. “The patient has recurrent ovarian cancer and did not tolerate tamoxifen, which is sometimes prescribed for ovarian cancer as well as breast cancer,” commented Steven Quay, M.D., Ph.D., Atossa’s President and CEO. “The patient recently underwent functional molecular genomic testing using 3D tumor organoid cultures grown in the laboratory from the patient’s tumor to help determine potential therapies. This testing revealed that the combination of Endoxifen and alpelisib produced an exceptional tumor response. We will follow the progress of this patient and consider additional clinical studies in patients with ovarian cancer.” Under the FDA expanded access program, the use of Atossa’s proprietary oral Endoxifen is restricted solely to this patient.
    • On March 31, Atossa announced their financial results for the fiscal year ended December 31, 2020, and provided an update on recent company developments. Read the complete story. 
    • On March 22, Atossa  announced that it had entered into a securities purchase agreement with institutional investors to purchase $50 million of its shares of common stock and warrants in a registered direct offering priced at-the-market under Nasdaq rules. Read the complete story.  Atossa has now raised ~$141M in gross proceeds (via registered directs and warrant exercises) since Dec. 2020 affording the company a significant development runway and many more options to be considering including acquisitions. 
    • On March 11, Atossa announced the FDA has issued a “Safe to Proceed” letter under their Expanded Access Pathway, permitting the use of Atossa’s oral Endoxifen as a treatment in an ovarian cancer patient. The patient is being treated at the University of Washington Medical Center by Dr. Barbara Goff, Surgeon-in-Chief. Under the FDA expanded access program, the use of Atossa’s proprietary oral Endoxifen is restricted solely to this patient. Approval from the Institutional Review Board (IRB) must be obtained prior to providing oral Endoxifen to this patient. Read the complete story.
    • On Feb. 25, Atossa announced final results from its Phase 1 double-blinded, randomized, placebo-controlled clinical study using Atossa’s proprietary drug candidate AT-301 administered by nasal spray. AT-301 was considered to be safe and well tolerated in healthy male and female participants in this study at two different dose levels over 14 days. AT-301 is being developed for at home use for patients recently diagnosed with COVID-19. There are currently no FDA-approved therapies to treat COVID-19 at home. Steven Quay, M.D., Ph.D., Atossa’s President and CEO stated, “The results from this study are very encouraging and we look forward to quickly commencing the next study of AT-301. We recently received input from the FDA on this program and based in part on that input, we are now preparing to conduct an additional pre-clinical study, which we expect to start this quarter. Following that, we expect to apply to the FDA to commence a Phase 2 study here in the United States.”
  •  
  •  


Economic Reports

  • On Monday, the macroeconomic schedule delivered the Treasury Budget report for March, which confirmed a $659.6B deficit vs a $119B deficit in the same period a year ago.  The fiscal year-to-date budget was also determined to deficit also stands at $1.71T vs. -$743.5B vs a year ago.
  • On Tuesday, the Total CPI report confirmed a rise by .6% m/m in March while the core CPI rose by .3% m/m. The NFIB Small Business Optimism Index report for March moved up to 98.2.
  • On Wednesday, the import prices report confirmed a rise by 1.2% in March while export prices rose 2.1% in March. The MBA Mortgage Applications Index report also showed a drop by 3.7%.
  • On Thursday, the March retail sales report confirmed and impressive 9.8% jump month/month that was surely bolstered by the stimulus measures that put free money in the hands of many Americans. The bar & restaurant industry saw an out weighted gain of 13.4% as more people got out and had money to burn.  The Initial jobless claims report for the week ending April 10 confirmed a drop by 193k to 576k while continuing claims for the week ending April 3 showed a rise of 4k to 3.731M. The total industrial production report confirmed a rise by 1.4% month/month in March while the capacity utilization rate moved higher to 74.4%. The Philadelphia Fed Index report showed a rise to 50.2 in April. The Empire State Manufacturing Survey rose to 26.3 in April. The NAHB Housing Market Index moved up to 83 in April. Business inventories rose .5% month/month in February.

Investing & Inspiration

  1. “It’s far better to buy a wonderful company at a fair price, than a fair company at a wonderful price.” – Warren Buffett
  2. “A market downturn doesn’t bother us. It is an opportunity to increase our ownership of great companies with great management at good prices.” — Warren Buffett
  3. “Every once in a while, the market does something so stupid it takes your breath away.” — Jim Cramer
  4. “The person who starts simply with the idea of getting rich won’t succeed; you must have a larger ambition.” — John D. Rockefeller
  5. “Know what you own, and know why you own it.” – Peter Lynch
  6. “Although it’s easy to forget sometimes, a share is not a lottery ticket… it’s part ownership of a business.” – Peter Lynch
  7. “Wise spending is part of wise investing. And it’s never too late to start.” – Rhonda Katz
  8. “Invest for the long haul. Don’t get too greedy and don’t get too scared.” – Shelby M.C. Davis

  9. “Fear incites human action far more urgently than does the impressive weight of historical evidence.”
    -Jeremy Siegel
  10. “With a good perspective on history, we can have a better understanding of the past and present, and thus a clear vision of the future.” — Carlos Slim Helu
  11. “If we like a business, we’re going to buy as much of it as we can and keep it as long as we can. And when we change our mind, we don’t take half measures.” – Warren Buffett
  12. “The most contrarian thing of all is not to oppose the crowd but to think for yourself.” — Peter Thiel

  13. “Never depend on a single income, make an investment to create a second source.” Warren Buffet

  14. Games are won by players who focus on the playing field –- not by those whose eyes are glued to the scoreboard.”
    ― Warren Buffett
  15. “The key to making money in stocks is not to get scared out of them.” – Peter Lynch
  16. “Courage taught me no matter how bad a crisis gets … any sound investment will eventually pay off.” — Carlos Slim Helu
  17. “Investing puts money to work. The only reason to save money is to invest it.” – Grant Cardone
  18. “As time goes on, I get more and more convinced that the right method of investment is to put fairly large sums into enterprises which one thinks one knows something about and in the management of which one thoroughly believes.” — John Maynard Keynes
  19. “Given a 10% chance of a 100 times payoff, you should take that bet every time.” — Jeff Bezos
  20. “Money is always eager and ready to work for anyone who is ready to employ it.” ― Idowu Koyenikan
  21. The secret to investing is to figure out the value of something – and then pay a lot less.” – Joel Greenblatt
  22. “We don’t have an analytical advantage, we just look in the right place.” – Seth Klarman
  23. “Men, it has been well said, think in herds. It will be seen that they go mad in herds, while they only recover their senses slowly, and one by one.” – Charles Mackay
  24. “It’s not whether you’re right or wrong that’s important, but how much money you make when you’re right and how much you lose when you’re wrong.” – George Soros
  25. “No Price is too low for a bear or too high for a bull.” — Anonymous
  26. “Investment is an asset or item that is purchased with the hope that it will generate income or appreciate in the future.” Anonymous
  27. “Behind every stock is a company. Find out what it’s doing.” — Peter Lynch
  28. “Wise spending is part of wise investing. And it’s never too late to start.” –Rhonda Katz
  29. “It amazes me how people are often more willing to act based on little or no data than to use data that is a challenge to assemble.” ― Robert Shiller
  30. “A bull market is like sex. It feels best just before it ends.” — Barton Biggs
  31. “The investor’s chief problem — even his worst enemy — is likely to be himself.” — Benjamin Graham
  32. “No profession requires more hard work, intelligence, patience, and mental discipline than successful speculation.” – Robert Rhea
  33. “Money is like a sixth sense – and you can’t make use of the other five without it.” – William Somerset Maugham
  34. “Compound interest is the eighth wonder of the world. He who understands it, earns it. He who doesn’t, pays it.” — Albert Einstein
  35. “Never count on making a good sale. Have the purchase price be so attractive that even a mediocre sale gives good results” — Warren Buffett
  36. “The stock market is a device for transferring money from the impatient to the patient.” – Warren Buffett
  37. “Thousands of experts study overbought indicators, head-and-shoulder patterns, put-call ratios, the Fed’s policy on money supply…and they can’t predict markets with any useful consistency, any more than the gizzard squeezers could tell the Roman emperors when the Huns would attack.” – Peter Lynch
  38. “Investing puts money to work. The only reason to save money is to invest it.” – Grant Cardone
  39. “You cannot save time for your future use however you can invest time for your future.” – John F. Heerdink, Jr. 
  40. “Know what you own, and know why you own it.” – Peter Lynch
  41. “Liquidity is only there when you don’t need it.” -Old Proverb
  42. “If you want to be a millionaire, start with a billion dollars and launch a new airline.” – Richard Branson
  43. “Fear incites human action far more urgently than does the impressive weight of historical evidence.” – Jeremy Siegel
  44. “In investing, what is comfortable is rarely profitable.” – Robert Arnott
  45. “Spend each day trying to be a little wiser than you were when you woke up.” – Charlie Munger
  46. “The entrance strategy is actually more important than the exit strategy.” – Edward Lampert
  47. “The rivers don’t drink their own water; Trees don’t eat their own fruits. The sun does not shine for itself, And flowers do not spread their fragrance For themselves. Living for others is a rule of nature” – Pope Francis
  48. “It is impossible to produce superior performance unless you do something different from the majority.” – John Templeton
  49. “An investment in knowledge pays the best interest.” – Benjamin Franklin.
  50. I believe the returns on investment in the poor are just as exciting as successes achieved in the business arena, and they are even more meaningful!” -Bill Gates
  51. “Every portfolio benefits from bonds; they provide a cushion when the stock market hits a rough patch. But avoiding stocks completely could mean your investment won’t grow any faster than the rate of inflation.” – Suze Orman
  52. “The tax on capital gains directly affects investment decisions, the mobility, and flow of risk capital… the ease or difficulty experienced by new ventures in obtaining capital, and thereby the strength and potential for growth in the economy.” – John F. Kennedy
  53. “If all the economists were laid end to end, they’d never reach a conclusion. -George Bernard Shaw
  54. “There are old traders and there are bold traders, but there are very few old, bold traders.”-Ed Seykota
  55. “Let this scenario play out on its own, in its own fashion. As you watch it unfold, you will soon be grateful that you choose the peaceful path. Remember — those who live by the sword, die by the sword.”
  56. “As long as you enjoy investing, you’ll be willing to do the homework and stay in the game.” -Jim Cramer
  57. “I rarely think the market is right. I believe non-dividend stocks aren’t much more than baseball cards. They are worth what you can convince someone to pay for it.” -Mark Cuban
  58. Michael Marcus taught me one other thing that is absolutely critical: You have to be willing to make mistakes regularly; there is nothing wrong with it. Michael taught me about making your best judgment, being wrong, making your next best judgment, being wrong, making your third best judgment, and then doubling your money.” -Bruce Kovner
  59. “The policy of being too cautious is the greatest risk of all.” -Jawaharlal Nehru
  60. “The only true test of whether a stock is “cheap” or “high” is not its current price in relation to some former price, no matter how accustomed we may have become to that former price, but whether the company’s fundamentals are significantly more or less favorable than the current financial-community appraisal of that stock.” -Philip Fisher
  61. “I learned to avoid trying to catch up or double up to recoup losses. I also learned that a certain amount of loss will affect your judgment, so you have to put some time between that loss and the next trade.” -Richard Dennis
  62. “The four most dangerous words in investing are: ‘this time it’s different.” -Sir John Templeton
  63. “Money doesn’t make you happy. I now have $50 million but I was just as happy when I had $48 million.” -Arnold Schwarzenegger

Videos

Please consider viewing these interesting videos: